Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.

Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.

Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.

Also Read: Abbott Laboratories’ Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst.

“Our results this quarter demonstrate the strength of our diversified business model,” said Robert Ford, chairman ...